Literature DB >> 20008301

Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myeloma.

Vito Racanelli1, Patrizia Leone, Maria Antonia Frassanito, Claudia Brunetti, Federico Perosa, Soldano Ferrone, Franco Dammacco.   

Abstract

We hypothesized that progression of monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM) reflects the escape of transformed plasma cells from T-cell recognition because of impaired antigen processing-presenting machinery (APM). We studied plasma cells and CD8(+) T cells from bone marrow of 20 MGUS patients, 20 MM patients, and 10 control patients. Immunofluorescence and flow cytometry revealed significantly different patterns of APM component expression in plasma cells from the 3 groups. Compared with control patients, MM samples had lower expression of proteasome subunits and peptide transporters and greater expression of chaperones, considering both percentages of stained cells and molecular equivalents of soluble fluorochrome. MGUS samples had intermediate percentages of stained cells but molecular equivalents of soluble fluorochrome similar to control patients. Real-time polymerase chain reaction documented that APM changes occurred at the transcriptional level. Cytotoxicity assays demonstrated that MGUS CD8(+) T cells lysed autologous transformed plasma cells more than MM CD8(+) T cells did. MGUS progression correlated directly with calnexin, calreticulin, and tapasin and indirectly with delta, LMP2, and LMP10 expression levels; MM disease status did not correlate with APM levels. APM changes may allow transformed plasma cells to elude immunesurveillance in the MGUS-MM pathogenetic sequence.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20008301      PMCID: PMC2826230          DOI: 10.1182/blood-2009-06-228676

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  31 in total

1.  Development and characterization of human constitutive proteasome and immunoproteasome subunit-specific monoclonal antibodies.

Authors:  N Bandoh; T Ogino; H S Cho; S Y Hur; J Shen; X Wang; S Kato; N Miyokawa; Y Harabuchi; S Ferrone
Journal:  Tissue Antigens       Date:  2005-09

2.  Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits.

Authors:  Antonia Busse; Marianne Kraus; Il-Kang Na; Anika Rietz; Carmen Scheibenbogen; Christoph Driessen; Igor Wolfgang Blau; Eckhard Thiel; Ulrich Keilholz
Journal:  Cancer       Date:  2008-02-01       Impact factor: 6.860

3.  Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma.

Authors:  Carmen Choi; Mathias Witzens; Marianna Bucur; Markus Feuerer; Nora Sommerfeldt; Andreas Trojan; Anthony Ho; Volker Schirrmacher; Hartmut Goldschmidt; Philipp Beckhove
Journal:  Blood       Date:  2004-11-23       Impact factor: 22.113

4.  A method to generate antigen-specific mAb capable of staining formalin-fixed, paraffin-embedded tissue sections.

Authors:  Xinhui Wang; Michael Campoli; Hyun Suk Cho; Takeshi Ogino; Nobuyuki Bandoh; Jijia Shen; Soo Young Hur; Toshiro Kageshita; Soldano Ferrone
Journal:  J Immunol Methods       Date:  2005-04-01       Impact factor: 2.303

Review 5.  Antigen presentation by MHC class I and its regulation by interferon gamma.

Authors:  K Früh; Y Yang
Journal:  Curr Opin Immunol       Date:  1999-02       Impact factor: 7.486

6.  Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma.

Authors:  Christian Jakob; Karl Egerer; Peter Liebisch; Seval Türkmen; Ivana Zavrski; Ulrike Kuckelkorn; Ulrike Heider; Martin Kaiser; Claudia Fleissner; Jan Sterz; Lorenz Kleeberg; Eugen Feist; Gerd-R Burmester; Peter-M Kloetzel; Orhan Sezer
Journal:  Blood       Date:  2006-11-09       Impact factor: 22.113

7.  Bone marrow of persistently hepatitis C virus-infected individuals accumulates memory CD8+ T cells specific for current and historical viral antigens: a study in patients with benign hematological disorders.

Authors:  Vito Racanelli; Maria Antonia Frassanito; Patrizia Leone; Claudia Brunetti; Simona Ruggieri; Franco Dammacco
Journal:  J Immunol       Date:  2007-10-15       Impact factor: 5.422

8.  Striking paucity of HLA-A, B, C and beta 2-microglobulin on human neuroblastoma cell lines.

Authors:  L A Lampson; C A Fisher; J P Whelan
Journal:  J Immunol       Date:  1983-05       Impact factor: 5.422

9.  Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas.

Authors:  M Kawano; T Hirano; T Matsuda; T Taga; Y Horii; K Iwato; H Asaoku; B Tang; O Tanabe; H Tanaka
Journal:  Nature       Date:  1988-03-03       Impact factor: 49.962

10.  Interleukin-6 inhibits apoptosis of malignant plasma cells.

Authors:  A Lichtenstein; Y Tu; C Fady; R Vescio; J Berenson
Journal:  Cell Immunol       Date:  1995-05       Impact factor: 4.868

View more
  31 in total

1.  Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells.

Authors:  Sabrina Chiesa; Silvia Morbelli; Sara Morando; Michela Massollo; Cecilia Marini; Arinna Bertoni; Francesco Frassoni; Soraya Tabera Bartolomé; Gianmario Sambuceti; Elisabetta Traggiai; Antonio Uccelli
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-29       Impact factor: 11.205

2.  Expression of antigen processing and presenting molecules in brain metastasis of breast cancer.

Authors:  Yan Liu; Yoshihiro Komohara; Natalie Domenick; Masasuke Ohno; Maki Ikeura; Ronald L Hamilton; Craig Horbinski; Xinhui Wang; Soldano Ferrone; Hideho Okada
Journal:  Cancer Immunol Immunother       Date:  2011-11-08       Impact factor: 6.968

3.  Myelomatous plasma cells display an aberrant gene expression pattern similar to that observed in normal memory B cells.

Authors:  Alicia Báez; José I Piruat; Teresa Caballero-Velázquez; Luís I Sánchez-Abarca; Isabel Álvarez-Laderas; M Victoria Barbado; Estefanía García-Guerrero; África Millán-Uclés; Jesús Martín-Sánchez; Mayte Medrano; José Antonio Pérez-Simón
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

Review 4.  Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma.

Authors:  Timothy R Rosean; Van S Tompkins; Guido Tricot; Carol J Holman; Alicia K Olivier; Fenghuang Zhan; Siegfried Janz
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

Review 5.  Therapeutic cancer vaccines: current status and moving forward.

Authors:  Jeffrey Schlom
Journal:  J Natl Cancer Inst       Date:  2012-03-06       Impact factor: 13.506

Review 6.  Myelomagenesis: capturing early microenvironment changes.

Authors:  Neha Korde; Irina Maric
Journal:  Semin Hematol       Date:  2011-01       Impact factor: 3.851

7.  Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8+ T-cell killing.

Authors:  Patrizia Leone; Simona Berardi; Maria Antonia Frassanito; Roberto Ria; Valli De Re; Sebastiano Cicco; Stefano Battaglia; Paolo Ditonno; Franco Dammacco; Angelo Vacca; Vito Racanelli
Journal:  Blood       Date:  2015-07-16       Impact factor: 22.113

Review 8.  Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.

Authors:  G Shay; L Hazlehurst; C C Lynch
Journal:  J Mol Med (Berl)       Date:  2015-10-01       Impact factor: 4.599

9.  Bone marrow endothelial cells sustain a tumor-specific CD8+ T cell subset with suppressive function in myeloma patients.

Authors:  Patrizia Leone; Giuseppe Di Lernia; Antonio Giovanni Solimando; Sebastiano Cicco; Ilaria Saltarella; Aurelia Lamanuzzi; Roberto Ria; Maria Antonia Frassanito; Maurilio Ponzoni; Paolo Ditonno; Franco Dammacco; Vito Racanelli; Angelo Vacca
Journal:  Oncoimmunology       Date:  2018-10-22       Impact factor: 8.110

Review 10.  Immunological and clinical significance of HLA class I antigen processing machinery component defects in malignant cells.

Authors:  Fernando Concha-Benavente; Raghvendra Srivastava; Soldano Ferrone; Robert L Ferris
Journal:  Oral Oncol       Date:  2016-06-02       Impact factor: 5.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.